Data for: Efficacy and long-term survival of advanced lung adenocarcinoma patients with uncommon EGFR mutations treated with 1st generation EGFR-TKIs compared with chemotherapy as first-line therapy

Name: Data for: Efficacy and long-term survival of advanced lung adenocarcinoma patients with uncommon EGFR mutations treated with 1st generation EGFR-TKIs compared with chemotherapy as first-line therapy
Creator: Huijuan Wang
Published: 2019-02-14T01:22:46.586Z
Keywords: National Institute of Clinical Excellence

Wang, Huijuan

doi:10.17632/by62p9c6hg.1

Data for: Efficacy and long-term survival of advanced lung adenocarcinoma patients with uncommon EGFR mutations treated with 1st generation EGFR-TKIs compared with chemotherapy as first-line therapy

Published: 14 February 2019| Version 1 | DOI: 10.17632/by62p9c6hg.1

Contributor:

Huijuan Wang

Description

Supplement 1. Major clinicopathological characteristics of 4276 cases.

Data for: Efficacy and long-term survival of advanced lung adenocarcinoma patients with uncommon EGFR mutations treated with 1st generation EGFR-TKIs compared with chemotherapy as first-line therapy

Description

Files

Categories

Licence